Patel Dinesh V PH D's Form 4/A amendment
AmendedProtagonist Therapeutics, Inc (PTGX) · filed May 14, 2026
- Accession no.
- 0001104659-26-061476
- Filed
- May 14, 2026
- Trade date
- May 12, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
- Original filed
- May 12, 2026
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $7.51M. It was filed 2 days after the trade.
This amendment replaces 0001104659-26-059591 (filed May 12, 2026).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Patel Dinesh V PH DCIK 0001120477 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | Common Stock | MOption exerciseAcquired | +75,000 | $21.58 | +$1,618,500 | 598,478 | Direct | |
| May 12, 2026 | Common Stock | SSaleDisposed | −75,000 | $100.12F2 | −$7,509,000 | 523,478 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | Common Stock | MOption exerciseDisposed | −75,000 | $0.00 | $0 | 225,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This Form 4 Amendment is being filed to clarify that the transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026 and to check the appropriate box which appeared unchecked on the original Form 4 filing.
- F2
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $98.83 to $103.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
These stock options are fully vested and will expire on October 11, 2026.